Limits...
Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-CT Scanning.

Shuai B, Shen L, Yang Y, Ma C, Zhu R, Xu X - PLoS ONE (2015)

Bottom Line: The impact of ovariectomy, the effect of estradiol, and the effect of zoledronic acid intervention on cancellous bone microstructure, as well as on the expression of β-catenin, were evaluated.The estradiol-treated and the zoledronic acid-treated group exhibited a significant increase in the bone volume fraction, trabecular number, trabecular thickness, bone surface to bone volume ratio (BS/BV), and β-catenin expression, when compared with those of the control group (P <0.01).In contrast, the structure model index, trabecular separation, and BS/BV were significantly lower compared with those of the model group (P <0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

ABSTRACT

Purpose/objective: Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic acid on the cancellous bone microstructure and its effect on the level of β-catenin in a mouse model of postmenopausal osteoporosis.

Methods and materials: 96 8-week-old specific-pathogen-free C57BL/6 mice were randomly divided into 4 groups (24 per group): a sham group, an ovariectomized osteoporosis model group, an estradiol-treated group, and a zoledronic acid-treated group. Five months after surgery, the third lumbar vertebra and left femur of the animals were dissected and scanned using micro-computed tomography (micro-CT) to acquire three-dimensional imagery of their cancellous bone microstructure. The impact of ovariectomy, the effect of estradiol, and the effect of zoledronic acid intervention on cancellous bone microstructure, as well as on the expression of β-catenin, were evaluated.

Results: The estradiol-treated and the zoledronic acid-treated group exhibited a significant increase in the bone volume fraction, trabecular number, trabecular thickness, bone surface to bone volume ratio (BS/BV), and β-catenin expression, when compared with those of the control group (P <0.01). In contrast, the structure model index, trabecular separation, and BS/BV were significantly lower compared with those of the model group (P <0.01). No differences were observed in the above parameters between animals of the zoledronic acid-treated and the estradiol-treated group.

Conclusion: These results suggest that increased β-catenin expression may be the mechanism underlying zoledronic acid-related improvement in the cancellous bone microstructure in ovariectomized mice. Our findings provide a scientific rationale for using zoledronic acid as a therapeutic intervention to prevent bone loss in post-menopausal women.

No MeSH data available.


Related in: MedlinePlus

Expression of β-catenin in each group (IHC, ×400).(1a-1d) Representatives of β-catenin staining in bone tissue cells in sham/normal group (1a), ovariectomized osteoporosis associated with estradiol-treated group (1b), ovariectomized osteoporosis associated with zoledronic acid-treated group (1c), and ovariectomized osteoporosis model group (1d). All photomicrographs images at 400x magnification.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4492783&req=5

pone.0132104.g001: Expression of β-catenin in each group (IHC, ×400).(1a-1d) Representatives of β-catenin staining in bone tissue cells in sham/normal group (1a), ovariectomized osteoporosis associated with estradiol-treated group (1b), ovariectomized osteoporosis associated with zoledronic acid-treated group (1c), and ovariectomized osteoporosis model group (1d). All photomicrographs images at 400x magnification.

Mentions: β-catenin expression per field of view was significantly lower in bone tissue cells of the ovariectomized osteoporosis model group compared with that in the sham group (P <0.01). In contrast, β-catenin expression in bone tissue cells of the estradiol-treated and the zoledronic acid-treated group was significantly higher than that in the ovariectomized osteoporosis model (P <0.01), but was significantly lower than that in the sham group (P <0.01). No differences in β-catenin expression were observed between bone tissue cells of the estradiol-treated and the zoledronic acid-treated group (Fig 1). Details of compared this β-Catenin expression have been described previously [20].


Assessment of the Impact of Zoledronic Acid on Ovariectomized Osteoporosis Model Using Micro-CT Scanning.

Shuai B, Shen L, Yang Y, Ma C, Zhu R, Xu X - PLoS ONE (2015)

Expression of β-catenin in each group (IHC, ×400).(1a-1d) Representatives of β-catenin staining in bone tissue cells in sham/normal group (1a), ovariectomized osteoporosis associated with estradiol-treated group (1b), ovariectomized osteoporosis associated with zoledronic acid-treated group (1c), and ovariectomized osteoporosis model group (1d). All photomicrographs images at 400x magnification.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4492783&req=5

pone.0132104.g001: Expression of β-catenin in each group (IHC, ×400).(1a-1d) Representatives of β-catenin staining in bone tissue cells in sham/normal group (1a), ovariectomized osteoporosis associated with estradiol-treated group (1b), ovariectomized osteoporosis associated with zoledronic acid-treated group (1c), and ovariectomized osteoporosis model group (1d). All photomicrographs images at 400x magnification.
Mentions: β-catenin expression per field of view was significantly lower in bone tissue cells of the ovariectomized osteoporosis model group compared with that in the sham group (P <0.01). In contrast, β-catenin expression in bone tissue cells of the estradiol-treated and the zoledronic acid-treated group was significantly higher than that in the ovariectomized osteoporosis model (P <0.01), but was significantly lower than that in the sham group (P <0.01). No differences in β-catenin expression were observed between bone tissue cells of the estradiol-treated and the zoledronic acid-treated group (Fig 1). Details of compared this β-Catenin expression have been described previously [20].

Bottom Line: The impact of ovariectomy, the effect of estradiol, and the effect of zoledronic acid intervention on cancellous bone microstructure, as well as on the expression of β-catenin, were evaluated.The estradiol-treated and the zoledronic acid-treated group exhibited a significant increase in the bone volume fraction, trabecular number, trabecular thickness, bone surface to bone volume ratio (BS/BV), and β-catenin expression, when compared with those of the control group (P <0.01).In contrast, the structure model index, trabecular separation, and BS/BV were significantly lower compared with those of the model group (P <0.01).

View Article: PubMed Central - PubMed

Affiliation: Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

ABSTRACT

Purpose/objective: Prompted by preliminary findings, this study was conducted to investigate the impact of zoledronic acid on the cancellous bone microstructure and its effect on the level of β-catenin in a mouse model of postmenopausal osteoporosis.

Methods and materials: 96 8-week-old specific-pathogen-free C57BL/6 mice were randomly divided into 4 groups (24 per group): a sham group, an ovariectomized osteoporosis model group, an estradiol-treated group, and a zoledronic acid-treated group. Five months after surgery, the third lumbar vertebra and left femur of the animals were dissected and scanned using micro-computed tomography (micro-CT) to acquire three-dimensional imagery of their cancellous bone microstructure. The impact of ovariectomy, the effect of estradiol, and the effect of zoledronic acid intervention on cancellous bone microstructure, as well as on the expression of β-catenin, were evaluated.

Results: The estradiol-treated and the zoledronic acid-treated group exhibited a significant increase in the bone volume fraction, trabecular number, trabecular thickness, bone surface to bone volume ratio (BS/BV), and β-catenin expression, when compared with those of the control group (P <0.01). In contrast, the structure model index, trabecular separation, and BS/BV were significantly lower compared with those of the model group (P <0.01). No differences were observed in the above parameters between animals of the zoledronic acid-treated and the estradiol-treated group.

Conclusion: These results suggest that increased β-catenin expression may be the mechanism underlying zoledronic acid-related improvement in the cancellous bone microstructure in ovariectomized mice. Our findings provide a scientific rationale for using zoledronic acid as a therapeutic intervention to prevent bone loss in post-menopausal women.

No MeSH data available.


Related in: MedlinePlus